Navigation Links
2013 Gastrointestinal Cancers Symposium reveals new advances for GI cancers
Date:1/22/2013

ALEXANDRIA, Va. New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held January 24-26, 2013, at The Moscone West Building in San Francisco, CA.

Five important studies were highlighted today in a live presscast:

  • Postoperative Treatment with S-1 Chemotherapy Reduces Relapses and Extends Survival in Patients with Pancreatic Cancer: Early results from a Phase III clinical trial conducted in Japan show patients who received the chemotherapy drug S-1 after surgery for Stage I-III pancreatic adenocarcinoma had a 44 percent lower risk of dying compared with patients treated with gemcitabine. While S-1 is not yet approved in the United States, it is available in several Asian and European countries.

  • New Molecular Classification System for Colorectal Cancer May Help Guide Treatment Choice for Individual Patients: Researchers identified three distinct colorectal cancer subtypes based on gene expression patterns in patients' tumors. The findings may lead to new molecular tests for determining if a patient needs adjuvant treatment and which treatment might be most beneficial.

  • Surgery Following Imatinib Therapy Substantially Improves Survival for Certain Patients with Gastrointestinal Stromal Tumors (GISTs): A new retrospective study validated the benefit of performing surgery to remove residual tumor lesions after imatinib therapy. Patients who received surgery after imatinib had a 5.5 fold lower risk of dying and a nearly 4-year longer time to disease worsening compared with those who received imatinib alone.

  • Profiling Gene Expression in Circulating Tumor Cells Shows Promise as a New Prognostic Strategy for Patients with Pancreatic Cancer: A study profiling gene expression in cells shed from pancreatic tumors into the bloodstream detected genomic changes associated with response and resistance to different treatments. This new profiling strategy may help predict whether or not a patient would respond to a particular chemotherapy regimen.

  • Second-Line Docetaxel Chemotherapy Improves Survival in Patients with Treatment-Resistant Esophageal or Gastric Cancers: A Phase III study showed that patients with esophageal or stomach cancers whose disease worsened despite first-line chemotherapy live on average 50 percent longer if they received second-line docetaxel than if they receive active symptom control (radiotherapy, steroids, and/or supportive medications). While docetaxel is already being used in this setting, the new study provides definitive evidence of survival benefit with second-line docetaxel.

"Research continues to deliver advances that will improve the lives of patients with gastrointestinal cancers, and we are learning to understand how to use molecular characteristics of tumors to choose and customize therapy for individual patients," said Neal J. Meropol, MD, who moderated the presscast. "At this conference, we will see the results of new studies showing life-extending treatments for some of our deadliest and hardest to treat cancers and new insights on tumor classification and prognosis."

Gastrointestinal cancers include those of the colon/rectum, stomach, pancreas, esophagus, small intestine, anus and other digestive organs. In 2012, it was estimated that nearly 285,000 people in the U.S. were diagnosed with these cancers and more than 142,000 will died from them.


'/>"/>

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. Gastroenterology Societies issue sedation curriculum for gastrointestinal endoscopy
3. Dietary fiber alters gut bacteria, supports gastrointestinal health
4. New analysis of drinking water-related gastrointestinal illness
5. Study Assesses Blood Thinner Use After Gastrointestinal Bleeding
6. Targeting neurotransmitter may help treat gastrointestinal conditions
7. Which Hospital Patients Need Drugs to Prevent Gastrointestinal Bleeding?
8. Potential new treatment for gastrointestinal cancers discovered
9. HPV-Related Head, Neck Cancers on the Rise
10. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
11. Kinase test may yield big gains for drug-resistant cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... IN (PRWEB) , ... May 05, 2016 , ... ... benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition to ... Smoak Benefits has a dedicated team of compliance, wellness, human resources, and health ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... community enrichment program serving families of greater Dubuque, IA. The current campaign fundraises ... and honorably discharged veterans. Donations to Veteran’s Freedom Center may now be made ...
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ZAC Foundation – ... partnership to reach nearly 1 million children with important water safety messages before summer ... leading cause of accidental death in children one to 6 years of age. ...
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Valeritas Holdings, Inc. (OTCQB: VLRX) ... offering (APO). This was accomplished via a reverse merger ... a private placement of approximately 5 million shares of ... Under the terms of the reverse merger, which ... will trade on the OTC Markets under the symbol ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Ischemic Stroke ...  report to their offering.       ... Global Acute Ischemic Stroke Market and ... into Acute Ischemic Stroke pipeline products, Acute ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
Breaking Medicine Technology: